ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

5 links0 made here, not in the record12 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule basedReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05323955Secondary BRain MetastasesPrevention After IsolatedIntracranial Progression onTrastuzumab/Pertuzumab orT-DM1 in Patients WithaDvanced Human EpidermalGrowth Factor Receptor 2+Carey Anders, M.D.Phase 2 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSBrain NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundAdo-Trastuzumab EmtansineEntry “Trastuzumab Emtansine (T-DM1)”…›Nov 2 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · TestedBackground · optionPertuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundTucatinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Trastuzumab

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Trastuzumab”the record gives no role
→judged→changed
How the 2 judgments split50%of judgments with a known value say Background
Background · 1
Tested · 1

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2TrastuzumabClaude Opus 5.5BackgroundCurrent
Nov 2Ado-Trastuzumab EmtansineClaude Opus 5.5TestedReplaced
Nov 2PertuzumabClaude Opus 5.5TestedReplaced
Nov 2TucatinibClaude Opus 5.5TestedReplaced
Nov 3PertuzumabClaude Opus 5.5BackgroundCurrent
Nov 10Ado-Trastuzumab EmtansineClaude Opus 5.5Background · optionCurrent
Nov 10TucatinibClaude Opus 5.5TestedCurrent
Nov 18TrastuzumabRule based · role ruleTestedOverridden
Nov 18Ado-Trastuzumab EmtansineRule based · role ruleTestedOverridden
Nov 18PertuzumabRule based · role ruleTestedOverridden
Nov 18TucatinibRule based · role ruleTestedAgrees
As of nowBrain NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.